Cormorant Asset Management, Lp - Net Worth and Insider Trading

Cormorant Asset Management, Lp Net Worth

The estimated net worth of Cormorant Asset Management, Lp is at least $2.3 Billion dollars as of 2024-12-27. Cormorant Asset Management, Lp is the 10% Owner of Ambrx Biopharma Inc and owns about 69,465,823 shares of Ambrx Biopharma Inc (AMAM) stock worth over $674 Million. Cormorant Asset Management, Lp is the of Prometheus Biosciences Inc and owns about 2,223,022 shares of Prometheus Biosciences Inc (RXDX) stock worth over $444 Million. Cormorant Asset Management, Lp is also the 10% Owner of Ambrx Biopharma Inc and owns about 11,231,000 shares of Ambrx Biopharma Inc (AMAM) stock worth over $314 Million. Besides these, Cormorant Asset Management, Lp also holds Turning Point Therapeutics Inc (TPTX) , Axonics Inc (AXNX) , Apellis Pharmaceuticals Inc (APLS) , Avidity Biosciences Inc (RNA) , EyePoint Pharmaceuticals Inc (EYPT) , Bright Minds Biosciences Inc (DRUG) , Kiniksa Pharmaceuticals International PLC (KNSA) , Design Therapeutics Inc (DSGN) , Corbus Pharmaceuticals Holdings Inc (CRBP) , Monte Rosa Therapeutics Inc (GLUE) , Olema Pharmaceuticals inc (OLMA) , Tyra Biosciences Inc (TYRA) , Akouos Inc (AKUS) , Immuneering Corp (IMRX) , Verve Therapeutics Inc (VERV) , Aerovate Therapeutics Inc (AVTE) , Rain Oncology Inc (RAIN) , Ventyx Biosciences Inc (VTYX) , Pyxis Oncology Inc (PYXS) , BioAtla Inc (BCAB) , Kezar Life Sciences Inc (KZR) , Proteostasis Therapeutics Inc (PTI) . Details can be seen in Cormorant Asset Management, Lp's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Cormorant Asset Management, Lp has not made any transactions after 2024-11-04 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Cormorant Asset Management, Lp

To

Cormorant Asset Management, Lp Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Cormorant Asset Management, Lp owns 36 companies in total, including Akouos Inc (AKUS) , Avidity Biosciences Inc (RNA) , and Turning Point Therapeutics Inc (TPTX) among others .

Click here to see the complete history of Cormorant Asset Management, Lp’s form 4 insider trades.

Insider Ownership Summary of Cormorant Asset Management, Lp

Ticker Comapny Transaction Date Type of Owner
AKUS Akouos Inc 2020-06-30 10 percent owner
RNA Avidity Biosciences Inc 2020-06-16 10 percent owner
TPTX Turning Point Therapeutics Inc 2019-04-22 10 percent owner
LIMIT LIMIT 2018-10-31 10 percent owner
LIMIT LIMIT 2018-07-18 10 percent owner
LIMIT LIMIT 2018-06-25 10 percent owner
LIMIT LIMIT 2018-05-29 10 percent owner
LIMIT LIMIT 2017-12-14 10 percent owner
LIMIT LIMIT 2017-11-13 10 percent owner
LIMIT LIMIT 2016-06-01 10 percent owner
LIMIT LIMIT 2014-08-15 10 percent owner
LIMIT LIMIT 2016-11-03 10 percent owner
LIMIT LIMIT 2020-10-29 10 percent owner
LIMIT LIMIT 2021-03-16 10 percent owner
LIMIT LIMIT 2021-04-27 10 percent owner
LIMIT LIMIT 2020-11-23 10 percent owner
LIMIT LIMIT 2022-12-20 director
LIMIT LIMIT 2021-10-13 10 percent owner
LIMIT LIMIT 2021-06-24 10 percent owner
LIMIT LIMIT 2021-07-28 10 percent owner
LIMIT LIMIT 2024-04-01 10 percent owner
LIMIT LIMIT 2021-07-02 10 percent owner
LIMIT LIMIT 2021-03-30 10 percent owner
LIMIT LIMIT 2021-06-28 10 percent owner
LIMIT LIMIT 2020-12-18 10 percent owner
LIMIT LIMIT 2022-01-06 10 percent owner
LIMIT LIMIT 2023-03-30 10 percent owner
LIMIT LIMIT 2021-06-21 10 percent owner
LIMIT LIMIT 2021-10-25 10 percent owner
LIMIT LIMIT 2021-09-17 10 percent owner
LIMIT LIMIT 2016-11-03 10 percent owner
LIMIT LIMIT 2023-09-18 10 percent owner
LIMIT LIMIT 2023-05-29 other: See below
LIMIT LIMIT 2023-05-29 other: See below
LIMIT LIMIT 2023-10-02 10 percent owner
LIMIT LIMIT 2023-10-23 10 percent owner

Cormorant Asset Management, Lp Latest Holdings Summary

Cormorant Asset Management, Lp currently owns a total of 25 stocks. Among these stocks, Cormorant Asset Management, Lp owns 69,465,823 shares of Ambrx Biopharma Inc (AMAM) as of September 18, 2023, with a value of $674 Million and a weighting of 29.45%. Cormorant Asset Management, Lp owns 2,223,022 shares of Prometheus Biosciences Inc (RXDX) as of March 16, 2021, with a value of $444 Million and a weighting of 19.42%. Cormorant Asset Management, Lp also owns 11,231,000 shares of Ambrx Biopharma Inc (AMAM) as of October 23, 2023, with a value of $314 Million and a weighting of 13.74%. The other 22 stocks Turning Point Therapeutics Inc (TPTX) , Axonics Inc (AXNX) , Apellis Pharmaceuticals Inc (APLS) , Avidity Biosciences Inc (RNA) , EyePoint Pharmaceuticals Inc (EYPT) , Bright Minds Biosciences Inc (DRUG) , Kiniksa Pharmaceuticals International PLC (KNSA) , Design Therapeutics Inc (DSGN) , Corbus Pharmaceuticals Holdings Inc (CRBP) , Monte Rosa Therapeutics Inc (GLUE) , Olema Pharmaceuticals inc (OLMA) , Tyra Biosciences Inc (TYRA) , Akouos Inc (AKUS) , Immuneering Corp (IMRX) , Verve Therapeutics Inc (VERV) , Aerovate Therapeutics Inc (AVTE) , Rain Oncology Inc (RAIN) , Ventyx Biosciences Inc (VTYX) , Pyxis Oncology Inc (PYXS) , BioAtla Inc (BCAB) , Kezar Life Sciences Inc (KZR) , Proteostasis Therapeutics Inc (PTI) have a combined weighting of 37.38% among all his current holdings.

Latest Holdings of Cormorant Asset Management, Lp

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
AMAM Ambrx Biopharma Inc 2023-09-18 69,465,823 9.70 673,818,483
RXDX Prometheus Biosciences Inc 2021-03-16 2,223,022 199.92 444,426,558
AMAM Ambrx Biopharma Inc 2023-10-23 11,231,000 28.00 314,468,000
TPTX Turning Point Therapeutics Inc 2019-04-22 3,099,099 76.01 235,562,515
AXNX Axonics Inc 2018-10-31 1,885,826 70.98 133,855,929
APLS Apellis Pharmaceuticals Inc 2017-11-13 3,473,925 32.75 113,771,044
RNA Avidity Biosciences Inc 2020-06-16 2,514,545 30.00 75,436,350
EYPT EyePoint Pharmaceuticals Inc 2024-05-06 8,325,000 7.19 59,856,750
DRUG Bright Minds Biosciences Inc 2024-11-04 1,059,331 39.88 42,246,120
KNSA Kiniksa Pharmaceuticals International PLC 2018-05-29 1,731,442 20.03 34,680,783
DSGN Design Therapeutics Inc 2021-03-30 5,114,844 6.25 31,967,775
CRBP Corbus Pharmaceuticals Holdings Inc 2024-09-20 2,375,000 12.75 30,281,250
GLUE Monte Rosa Therapeutics Inc 2021-06-28 3,202,200 7.06 22,607,532
OLMA Olema Pharmaceuticals inc 2020-11-23 3,270,544 6.15 20,113,846
TYRA Tyra Biosciences Inc 2021-09-17 1,069,932 14.07 15,053,943
AKUS Akouos Inc 2020-06-30 789,989 13.29 10,498,954
IMRX Immuneering Corp 2024-04-01 2,895,273 2.33 6,745,986
VERV Verve Therapeutics Inc 2021-06-21 984,224 6.00 5,900,423
AVTE Aerovate Therapeutics Inc 2021-07-02 2,030,691 2.67 5,421,945
RAIN Rain Oncology Inc 2021-04-27 2,776,657 1.21 3,359,755
VTYX Ventyx Biosciences Inc 2021-10-25 1,410,303 2.38 3,356,521
PYXS Pyxis Oncology Inc 2021-10-13 1,118,854 1.59 1,778,978
BCAB BioAtla Inc 2020-12-18 2,292,060 0.64 1,462,334
KZR Kezar Life Sciences Inc 2018-06-25 188,840 6.64 1,253,898
PTI Proteostasis Therapeutics Inc 2017-12-14 165,000 1.11 183,150

Holding Weightings of Cormorant Asset Management, Lp


Cormorant Asset Management, Lp Form 4 Trading Tracker

According to the SEC Form 4 filings, Cormorant Asset Management, Lp has made a total of 4 transactions in Ambrx Biopharma Inc (AMAM) over the past 5 years, including 4 buys and 0 sells. The most-recent trade in Ambrx Biopharma Inc is the acquisition of 2,152,738 shares on September 18, 2023, which cost Cormorant Asset Management, Lp around $20 Million.

According to the SEC Form 4 filings, Cormorant Asset Management, Lp has made a total of 1 transactions in Prometheus Biosciences Inc (RXDX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Prometheus Biosciences Inc is the acquisition of 375,000 shares on March 16, 2021, which cost Cormorant Asset Management, Lp around $7 Million.

According to the SEC Form 4 filings, Cormorant Asset Management, Lp has made a total of 1 transactions in Ambrx Biopharma Inc (AMAM) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Ambrx Biopharma Inc is the acquisition of 1,307,311 shares on October 23, 2023, which cost Cormorant Asset Management, Lp around $9 Million.

More details on Cormorant Asset Management, Lp's insider transactions can be found in the Insider Trading History of Cormorant Asset Management, Lp table.

Insider Trading History of Cormorant Asset Management, Lp

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Cormorant Asset Management, Lp Trading Performance

GuruFocus tracks the stock performance after each of Cormorant Asset Management, Lp's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Cormorant Asset Management, Lp is 21.27%. GuruFocus also compares Cormorant Asset Management, Lp's trading performance to market benchmark return within the same time period. The performance of stocks bought by Cormorant Asset Management, Lp within 3 months outperforms 26 times out of 37 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Cormorant Asset Management, Lp's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Cormorant Asset Management, Lp

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
5 out of 28 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 7.29 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 4.37 LIMIT LIMIT LIMIT LIMIT LIMIT

Cormorant Asset Management, Lp Ownership Network

Ownership Network List of Cormorant Asset Management, Lp

No Data

Ownership Network Relation of Cormorant Asset Management, Lp

Insider Network Chart

Cormorant Asset Management, Lp Owned Company Details

What does Akouos Inc do?

Who are the key executives at Akouos Inc?

Cormorant Asset Management, Lp is the 10 percent owner of Akouos Inc. Other key executives at Akouos Inc include 10 percent owner Kearny Acquisition Corp , 10 percent owner Lilly Eli & Co , and Chief Operating Officer Jennifer Anne Wellman .

Akouos Inc (AKUS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Akouos Inc (AKUS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Akouos Inc (AKUS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Akouos Inc (AKUS)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Akouos Inc Insider Transactions

No Available Data

Cormorant Asset Management, Lp Mailing Address

Above is the net worth, insider trading, and ownership report for Cormorant Asset Management, Lp. You might contact Cormorant Asset Management, Lp via mailing address: 200 Clarendon Street, 52nd Floor, Boston Ma 02116.

Discussions on Cormorant Asset Management, Lp

No discussions yet.